117 related articles for article (PubMed ID: 10425175)
1. Inhibition of mutant p53 phosphorylation at serine 15 or serine 315 partially restores the function of wild-type p53.
Sugikawa E; Yazaki N; Tsunoda S; Nakanishi N; Ohashi M
Biochem Biophys Res Commun; 1999 Aug; 261(2):256-63. PubMed ID: 10425175
[TBL] [Abstract][Full Text] [Related]
2. Specific DNA binding by p53 is independent of mutation at serine 389, the casein kinase II site.
Rolley N; Milner J
Oncogene; 1994 Oct; 9(10):3067-70. PubMed ID: 8084615
[TBL] [Abstract][Full Text] [Related]
3. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.
Pospísilová S; Brázda V; Kucharíková K; Luciani MG; Hupp TR; Skládal P; Palecek E; Vojtesek B
Biochem J; 2004 Mar; 378(Pt 3):939-47. PubMed ID: 14640983
[TBL] [Abstract][Full Text] [Related]
4. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases.
Wang Y; Prives C
Nature; 1995 Jul; 376(6535):88-91. PubMed ID: 7596441
[TBL] [Abstract][Full Text] [Related]
5. Cdk2 kinase phosphorylates serine 315 of human p53 in vitro.
Price BD; Hughes-Davies L; Park SJ
Oncogene; 1995 Jul; 11(1):73-80. PubMed ID: 7624134
[TBL] [Abstract][Full Text] [Related]
6. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities.
Fiscella M; Zambrano N; Ullrich SJ; Unger T; Lin D; Cho B; Mercer WE; Anderson CW; Appella E
Oncogene; 1994 Nov; 9(11):3249-57. PubMed ID: 7936649
[TBL] [Abstract][Full Text] [Related]
7. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression.
Fiscella M; Ullrich SJ; Zambrano N; Shields MT; Lin D; Lees-Miller SP; Anderson CW; Mercer WE; Appella E
Oncogene; 1993 Jun; 8(6):1519-28. PubMed ID: 8502477
[TBL] [Abstract][Full Text] [Related]
8. Potentiality of DNA-dependent protein kinase to phosphorylate Ser46 of human p53.
Komiyama S; Taniguchi S; Matsumoto Y; Tsunoda E; Ohto T; Suzuki Y; Yin HL; Tomita M; Enomoto A; Morita A; Suzuki T; Ohtomo K; Hosoi Y; Suzuki N
Biochem Biophys Res Commun; 2004 Oct; 323(3):816-22. PubMed ID: 15381073
[TBL] [Abstract][Full Text] [Related]
9. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation.
Kapoor M; Hamm R; Yan W; Taya Y; Lozano G
Oncogene; 2000 Jan; 19(3):358-64. PubMed ID: 10656682
[TBL] [Abstract][Full Text] [Related]
10. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
Sugikawa E; Tsunoda S; Nakanishi N; Ohashi M
Anticancer Res; 2001; 21(4A):2671-5. PubMed ID: 11724337
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of p53/p21Cip1/Waf1 pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation.
Bulavin DV; Tararova ND; Aksenov ND; Pospelov VA; Pospelova TV
Oncogene; 1999 Oct; 18(41):5611-9. PubMed ID: 10523840
[TBL] [Abstract][Full Text] [Related]
12. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis.
Powers JT; Hong S; Mayhew CN; Rogers PM; Knudsen ES; Johnson DG
Mol Cancer Res; 2004 Apr; 2(4):203-14. PubMed ID: 15140942
[TBL] [Abstract][Full Text] [Related]
13. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
[TBL] [Abstract][Full Text] [Related]
14. DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin.
Take Y; Kumano M; Teraoka H; Nishimura S; Okuyama A
Biochem Biophys Res Commun; 1996 Apr; 221(2):207-12. PubMed ID: 8619835
[TBL] [Abstract][Full Text] [Related]
15. Characterization of protein kinase activities associated with p53-large-T immune complexes from SV40-transformed rat cells.
Müller E; Boldyreff B; Scheidtmann KH
Oncogene; 1993 Aug; 8(8):2193-205. PubMed ID: 8393163
[TBL] [Abstract][Full Text] [Related]
16. The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53.
Lakin ND; Hann BC; Jackson SP
Oncogene; 1999 Jul; 18(27):3989-95. PubMed ID: 10435622
[TBL] [Abstract][Full Text] [Related]
17. p53 mediates bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway.
Thomas A; Giesler T; White E
Oncogene; 2000 Nov; 19(46):5259-69. PubMed ID: 11077443
[TBL] [Abstract][Full Text] [Related]
18. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.
Luciani MG; Hutchins JR; Zheleva D; Hupp TR
J Mol Biol; 2000 Jul; 300(3):503-18. PubMed ID: 10884347
[TBL] [Abstract][Full Text] [Related]
19. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage.
Jimenez GS; Bryntesson F; Torres-Arzayus MI; Priestley A; Beeche M; Saito S; Sakaguchi K; Appella E; Jeggo PA; Taccioli GE; Wahl GM; Hubank M
Nature; 1999 Jul; 400(6739):81-3. PubMed ID: 10403253
[TBL] [Abstract][Full Text] [Related]
20. Role of MAP kinases in UVB-induced phosphorylation of p53 at serine 20.
She QB; Ma WY; Dong Z
Oncogene; 2002 Feb; 21(10):1580-9. PubMed ID: 11896587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
